The company shared validation data this week that it said led the FDA to approve use of the test in a new prospective trial of Roche's Tecentriq in NSCLC.
Genome and transcriptome sequences from hundreds of pediatric cancer cases led to somatic mutations and fusions suspected of producing potentially targetable antigens.
Earlier this week, the company's scientific co-founders published an improved version of the ATAC-seq method that allows them to analyze frozen tissue.
The changes include recommendations for first line immunotherapy in patients with high PD-L1 expression, and clarification on use of targeted therapies.
The National Cancer Institute-led team used a CRISPR-based approach to identify genes like APLNR that, when mutated, make cancers resistant to immunotherapy.
News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.
